DATASHEET - Medsafe
CCDS180124v007 Page 1 of 12 MOTILIUM(180601)DDS MOTILIUM® domperidone. DATASHEET 1. PRODUCT NAME Motilium 10 mg film-coated tablets 2. QUALITATIVE AND Q UANTITATIVE COMPOSITION
Download DATASHEET - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION ... - …
www.aloxi.com1 INDICATIONS AND USAGE 1.1 Chemotherapy-Induced Nausea and Vomiting in Adults ALOXI is indicated for:
DRUG NAME: Crizotinib - BC Cancer
www.bccancer.bc.caCrizotinib BC Cancer Agency Cancer Drug Manual© Page 2 of 6 Crizotinib Developed: 1 April 2014 Revised: 1 September 2014. Caution: • vision disorders. have been reported; ability to drive or operate machinery may be compromised.
DRUG NAME: Degarelix - BC Cancer
www.bccancer.bc.caDegarelix BC Cancer Agency Cancer Drug Manual© Page 1 of 6 Degarelix Developed: 1 February 2015 Revised: DRUG NAME: Degarelix SYNONYM(S): degarelix acetate …
DRUG INDUCED QT PROLONGATION - GGC …
www.ggcprescribing.org.ukIssue 21, December 2012 Produced by NHS Greater Glasgow and Clyde Medicines Information Service . DRUG INDUCED QT PROLONGATION Prolongation of the QT interval can lead to a
DATASHEET - Medsafe Home Page
www.medsafe.govt.nznozinan-ccsiv1-dsv11-18jan17 1 DATASHEET NOZINAN ® NAME OF THE MEDICINE Levomepromazine hydrochloride 25mg/mLinjection. Levomepromazine maleate …
TQT Studies: Their Impact on Drug Development …
www.richmondpharmacology.comTQT Studies: Their Impact on Drug Development and the Key Elements of a Successful TQT Study Asif Naseem, Keith Berelowitz, Ulrike Lorch, Radivoj Arezina and Jorg Taubel
QT PROLONGATION and TORSADES DE POINTES: …
www.rxfiles.caThe Rx Files: Q&A Summary Mar, 2005 S. Downey BSP, B. Jensen BSP, L.Regier BSP, BA PROMOTING OPTIMAL DRUG THERAPY www.RxFiles.ca QT PROLONGATION and TORSADES DE POINTES: DRUGS and SUDDEN DEATH
ECG Manifestations: The Poisoned Patient
www.ubccriticalcaremedicine.caECG Manifestations: The Poisoned Patient Christopher P. Holstege, MD*, David L. Eldridge, MD, Adam K. Rowden, DO Division of Medical Toxicology, Department of Emergency Medicine,